查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
病毒和非病毒载体制造市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按载体类型、按适应症、按应用、按公司和区域划分
市场调查报告书
商品编码
1289659

病毒和非病毒载体制造市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按载体类型、按适应症、按应用、按公司和区域划分

Viral & Non-Viral Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Vector Type, By Indication, By Application, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球病毒和非病毒载体制造市场预计将在2023-2027年的预测期间出现令人印象深刻的增长。主要因素包括致命疾病的流行率上升，基因和细胞治疗产品的日益突出，以及技术的广泛发展，这些都推动了市场的增长。载体是基因传递的工具，它将遗传物质传递到核细胞中。它们有两种类型，病毒载体和非病毒载体。病毒载体是FDA批准的基因疗法中常用的传递工具，而非病毒载体的安全性和有效性仍在研究中。支持市场增长的其他因素有：广泛的研究和开发，越来越多的病人，越来越多的临床研究，私人以及公共部门的各种投资，基于载体的基因和细胞治疗越来越普遍，公司之间的合作越来越多，以及对定制药物的高需求。

致命疾病的发病率不断上升

遗传性疾病、癌症和传染病，如糖尿病、唐氏综合症、流感、肝癌、阿尔茨海默病、心血管疾病和其他疾病，在全球范围内的发生率越来越高，这促进了市场的增长。根据世卫组织的数据，心血管疾病（CVDs）是全球死亡的主要原因，每年夺去约1790万人的生命。按照世卫组织的说法，癌症是一个主要的死亡原因，报告了近1000万例死亡，或在2020年近六分之一的死亡。由于患有这些致命疾病的病人越来越多，对用于治疗的载体的需求正在上升。例如，在2019年，美国食品和药物管理局批准了MVA（改良的安卡拉疫苗病毒），市场名称为Jynneos，用于预防天花和猴痘。

基因和细胞治疗产品的地位日益突出

基因疗法是一种借助于遗传物质来治疗或预防疾病的方法。先进的基因和细胞疗法，通过使用载体，对生物医学领域产生了很大的影响。经过各种研究，人们发现，载体不仅用于预防或治疗特定的疾病，而且利用它们所具有的遗传信息，可以直接针对疾病的原因，并能改变细胞的功能方式。基于载体的基因和细胞治疗的普及率不断提高，也是市场增长的一个因素。因此，众多创新公司正积极参与开发和生产用于细胞和基因治疗的病毒载体和非病毒载体。例如，在2022年，美国FDA批准了第二个CAR-T疗法，名为CARVYKTI（TM），由强生公司开发，用于治疗复发或难治性多发性骨髓瘤。

可用的定制方法

利用给定的市场数据，TechSci Research根据公司的具体需要提供定制服务。该报告可提供以下定制选项：

公司信息

  • 其他市场参与者（最多5家）的详细分析和概况。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19对全球病毒和非病毒载体制造市场的影响

第五章：客户的声音

第六章：全球病毒和非病毒载体制造市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额和预测
    • 按载体类型（病毒性载体和非病毒性载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按地区分类
    • 按公司分类 (2021年)
  • 市场地图

第七章：北美病毒和非病毒载体制造市场展望

  • 市场规模和预测
    • 按价值分类
  • 市场份额与预测
    • 按载体类型（病毒性载体和非病毒性载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按国家分类
  • 北美洲：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第8章：欧洲病毒和非病毒载体制造市场前景

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按载体类型（病毒性载体和非病毒性载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按国家分类
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第九章：亚太地区病毒和非病毒载体制造市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按载体类型（病毒性载体和非病毒性载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按国家分类
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第十章：南美病毒和非病毒载体制造市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按载体类型（病毒性载体和非病毒性载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按国家分类
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第11章 ：中东和非洲病毒和非病毒载体制造市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额和预测
    • 按载体类型（病毒载体与非病毒载体）分类
    • 按适应症（癌症、遗传病、传染病、心血管疾病、其他）分类
    • 按应用（基因治疗、疫苗学、细胞治疗、其他）分类
    • 按国家分类
  • MEA: 国家分析
    • 南非病毒和非病毒载体制造
    • 沙特阿拉伯病毒和非病毒载体制造
    • 阿联酋病毒和非病毒载体制造

第12章 ：市场动态

  • 驱动力
  • 挑战

第十三章 ：市场趋势与发展

第14章：竞争格局

  • Catalent, Inc.FUJIFILM Holdings Corporation Danaher Corporation Genscript Biotech Corporation Lonza Group AG Merck KGaA Inc.Oxford Biomedica plc Sartorius AG Takara Bio Inc.赛默飞世尔科技公司

第十五章：战略建议

简介目录
Product Code: 13100

The global viral & non-viral vector manufacturing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the rising prevalence of fatal diseases, the growing prominence of gene and cell therapy products, and extensive development in technology, which are propelling the growth of the market. Vectors are tools for gene delivery, which deliver genetic material into the nucleic cell. They are of two types, viral and non-viral vectors. Viral vectors are commonly used delivery vehicles in FDA-approved gene therapies, whereas non-viral are still studied for their safety and efficacy. The other factors supporting the market's growth are the extensive research and development, an increasing number of patients, an increasing number of clinical studies, various investments by private as well public sectors, increasing prevalence of vector-based gene and cell treatments, the growing number of collaborations between companies, and the high demand for customized medications.

Rising Prevalence of Fatal Diseases

The increasing occurrence of genetic disorders, cancers, and infectious diseases, such as diabetes, down syndrome, flu, liver cancer, Alzheimer's disease, cardiovascular diseases, and others, across the globe are bolstering the growth of the market. According to the WHO, Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking approximately 17.9 million lives each year. As per WHO, cancer is a leading cause of death, reporting almost 10 million deaths, or nearly one in six deaths in 2020. Owing to the increasing number of patients suffering from these fatal diseases, the demand for vectors for treatment is rising. For instance, in 2019, the FDA approved MVA (Modified Vaccinia virus Ankara), under the market name Jynneos, to prevent both smallpox and monkeypox.

Growing Prominence of Gene and Cell Therapy Products

Gene therapy is a method to treat or prevent disease with the help of genetic material. Advanced gene and cell therapies, with the use of vectors, have considerably impacted the field of biomedicine. After various research, it is found that the vectors are not only used to prevent or treat specific diseases, but with the genetic information they have, they can directly target the cause of the disease and can alter the way a cell functions. The rising prevalence of vector-based gene and cell treatments is also a contributing factor to the growth of the market. Therefore, numerous innovator companies are actively involved in the development and production of viral vectors and non-viral vectors for cell and gene therapies. For instance, in 2022, the USFDA approved the second CAR-T therapy named CARVYKTI™, developed by Johnson and Johnson, which is used for the treatment of relapsed or refractory multiple myeloma.

Market Segmentation

The global viral & non-viral vector manufacturing market is segmented into vector type, indication, application, and company. Based on vector type, the market is segmented into viral vector and non-viral vector. Based on viral vector, the market is further segmented into adenoviral vector, retroviral vector, lentiviral vector, vaccinia viral vector, and others. Based on non-viral vector, the market is further segmented into plasmid DNA, lipid-based non-viral vector, polymer-based non-viral vector, and others. Based on indication, the market is divided into cancer, genetic disease, infectious disease, cardiovascular diseases, and others. Based on application, the market is divided into gene therapy, vaccinology, cell therapy, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of genetic disorders, infectious diseases, chronic diseases, and cancers in the country.

Market Players

Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., and Thermo Fisher Scientific Inc are some of the leading companies operating in the market.

Report Scope

In this report, global viral & non-viral vector manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Viral & Non-Viral Vector Manufacturing Market, By Vector Type:

  • Viral Vector
    • Adenoviral Vector
    • Retroviral Vector
    • Lentiviral Vector
    • Vaccinia Viral Vector
    • Others
  • Non-Viral Vector
    • Plasmid DNA
    • Lipid-Based Non-Viral Vector
    • Polymer-Based Non-Viral Vector
    • Others

Viral & Non-Viral Vector Manufacturing Market, By Indication:

  • Cancer
  • Genetic Disease
  • Infectious Disease
  • Cardiovascular Diseases
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Application:

  • Gene Therapy
  • Vaccinology
  • Cell Therapy
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Viral & Non-Viral Vector Manufacturing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Viral & Non-Viral Vector Manufacturing Market

5. Voice of Customer

6. Global Viral & Non-Viral Vector Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 6.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 6.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 6.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 6.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2021)
  • 6.3. Market Map

7. North America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 7.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 7.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 7.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 7.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Application

8. Europe Viral & Non-Viral Vector Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 8.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 8.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 8.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 8.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Application
    • 8.3.2. Germany Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Application
    • 8.3.3. United Kingdom Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Application
    • 8.3.4. Italy Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Application
    • 8.3.5. Spain Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Application

9. Asia-Pacific Viral & Non-Viral Vector Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 9.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 9.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 9.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 9.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Application
    • 9.3.2. India Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Application
    • 9.3.3. Japan Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Application
    • 9.3.4. South Korea Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Application
    • 9.3.5. Australia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Application

10. South America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 10.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 10.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 10.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 10.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Application
    • 10.3.2. Argentina Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Application
    • 10.3.3. Colombia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Application

11. Middle East and Africa Viral & Non-Viral Vector Manufacturing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 11.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 11.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 11.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 11.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Application
    • 11.3.2. Saudi Arabia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Application
    • 11.3.3. UAE Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Catalent, Inc.
  • 14.2. FUJIFILM Holdings Corporation
  • 14.3. Danaher Corporation
  • 14.4. Genscript Biotech Corporation
  • 14.5. Lonza Group AG
  • 14.6. Merck KGaA Inc.
  • 14.7. Oxford Biomedica plc
  • 14.8. Sartorius AG
  • 14.9. Takara Bio Inc.
  • 14.10. Thermo Fisher Scientific Inc

15. Strategic Recommendations